South Korea
· Delayed Price · Currency is KRW Dx & Vx Company Description
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea.
The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services.
It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs.
Its pipeline includes Vx product, oral pediatric Covid19/influenza vaccine; new anti-cancer antibody drug; an antibody drug utilizing advanced mRNA vaccine development technique; Vx Microbiome R&D pipeline, a bacterial vaccine against respiratory diseases, new drugs targeting obesity and diagnosis etc; and Oxford Vacmedix Vaccine, an anti-cancer vaccineutilizing ROP technology.
It has a research collaboration with bereum, Bioapp, CORESTEMCHEMON, Genscript PROBIO, JOINTOWN PHARMACEUTICAL GROUP,etc. The company was formerly known as Cancer Rop Co., Ltd. and changed its name to Dx & Vx Co., Ltd. in January 2022.
The company was founded in 2001 and is based in Seoul, South Korea.
| Country | South Korea |
| Founded | 2001 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 112 |
| CEO | Yong Gu Lee |
Contact Details
Address: Elysia Building 173 Seoul South Korea | |
| Phone | 82 2 890 8700 |
| Website | dxvx.com |
Stock Details
| Ticker Symbol | 180400 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Yong Gu Lee | Chief Executive Officer |